Chief Medical Officer
Chief Development Officer
NMD Pharma is a promising Danish biotechnology company dedicated to the development of a paradigm, innovative and life-changing treatment for patients with reduced muscle function due to compromised neuromuscular transmission as experienced in Myasthenia Gravis and other rare neuromuscular disorders.
Following an impressive Series A funding round in 2018, backed by major venture capital players, the NMD Pharma Founders and Board engaged Tom Bradley and Stuart Penney to undertake two key searches for a Chief Medical Officer and Chief Development Officer to compliment the advancement of NMD Pharma key programmes towards clinical development.
These senior hires demanded a deep understanding of neurological disease and a track-record of clinical development within a growth stage biotech which required an in-depth international search across the US and Europe. The outcome of which led to successful hire of both roles, with candidates hailing from the US and UK respectively.
“Tom and Stuart steered a highly professional and efficient process to recruit top-end professionals for these critical positions in NMD. The collaboration that NMD Pharma has had with Tom and Stuart has ensured that a strong management team is now in place to drive the development of the NMD Pharma technology forward.”
Thomas Holm Pedersen, CEO, NMD Pharma